Clinical Guides
Pulmonary Tuberculosis
An India-focused guide to diagnosing pulmonary tuberculosis, assessing infectiousness, notifying disease, delivering programme-aligned treatment, and protecting contacts. It is written for supervised learning and keeps microbiological confirmation, resistance testing, infection prevention, HIV and pregnancy review, adverse-effect surveillance, nutrition, stigma-sensitive communication and programme referral together.
MedNext Academy | 12 min read
Pulmonary Tuberculosis
An India-focused guide to diagnosing pulmonary tuberculosis, assessing infectiousness, notifying disease, delivering programme-aligned treatment, and protecting contacts. It is written for supervised learning and keeps microbiological confirmation, resistance testing, infection prevention, HIV and pregnancy review, adverse-effect surveillance, nutrition, stigma-sensitive communication and programme referral together.
Summary
Pulmonary tuberculosis (TB) is infection of the lungs by Mycobacterium tuberculosis complex and may be contagious when organisms are aerosolised from airways. Symptoms can be prolonged cough, fever, night sweats, weight loss, fatigue, chest pain or haemoptysis, but illness may be subtle, especially with HIV, diabetes, malnutrition, older age or immunosuppression. A normal chest radiograph does not safely exclude disease and an abnormal image does not prove TB. Diagnosis should combine clinical assessment, chest imaging and microbiological testing, with drug-resistance information obtained as early as possible.
India's National Tuberculosis Elimination Programme (NTEP) prioritises rapid molecular testing, notification, adherence support, contact investigation and drug-susceptibility-guided treatment. Sputum microscopy can support assessment but a negative smear does not exclude paucibacillary disease. Xpert MTB/RIF or another approved molecular test can detect M tuberculosis and rifampicin resistance; line-probe or culture-based testing may define additional resistance. Do not treat a positive molecular result as permission to ignore clinical severity, extrapulmonary disease or an alternative diagnosis.
Separate infection-control actions begin at first suspicion: mask the patient, improve ventilation, reduce crowding and use respiratory protection for staff during aerosol-generating procedures. Confirmed disease is notified through the current national system. Regimen, doses, duration, monitoring and interruption management must follow current NTEP guidance and an authorised TB clinician. This educational draft remains reviewed educational guide.
How Common Is It?
TB remains a major public-health problem in India, but national notification counts are surveillance measures affected by access, testing, private-sector reporting and the distinction between incident disease and prevalent infection. A service should not use a population number to reassure an individual with chronic cough or to infer resistance. Delayed diagnosis permits transmission and worsens disease, while indiscriminate testing or labelling can cause stigma and unnecessary treatment.
Pulmonary disease is common among notified TB, yet the presentation varies from cavitary upper-lobe disease to lower-zone, miliary or minimally abnormal imaging. Children, people with HIV, diabetes, renal disease, silicosis, undernutrition or immunosuppression may have atypical symptoms and imaging. A person who feels well can still have microbiologically confirmed disease and transmit infection, while cough from another illness can coexist with a positive latent-infection test.
India's public and private care pathways differ in specimen transport, molecular testing, culture, drug-resistance access, counselling and follow-up. NTEP notification and free programme medicines are important, but patients may move between providers or use unregulated combinations. Ask where a patient has already tested or received medicines, reconcile every strip and preserve prior results. Burden also includes lost wages, housing insecurity, food insecurity, treatment stigma and adverse effects; adherence support must address these realities rather than frame every interruption as wilful non-compliance.
Risk Factors
Risk factors increase the likelihood or consequence of pulmonary TB but do not diagnose it. Close household or congregate exposure, previous TB, HIV, diabetes, undernutrition, silicosis, chronic kidney disease, smoking, harmful alcohol use, corticosteroids, transplant medicines, anti-TNF therapy and other immunosuppression matter. Crowded housing, prisons, shelters, hostels, mines, health facilities and poorly ventilated workplaces can amplify transmission. Ask about migration, travel and prior care without stereotyping.
History should include prior regimens, adherence, drug resistance, contact with a person with pulmonary TB, HIV testing and treatment, diabetes, pregnancy, liver or kidney disease, visual symptoms, neuropathy, psychiatric illness and medicines that interact with rifamycins. A previous incomplete course is not simply “relapse”; obtain records and test resistance. Household contacts, children under five and immunocompromised contacts need prompt evaluation.
Risk assessment includes practical determinants: food, transport to a testing centre, wages lost for appointments, privacy, language, gender safety and ability to store medicines. Avoid asking a patient to choose between income and treatment without social support. Smoking cessation and diabetes control improve health but do not replace antimycobacterial treatment. TB risk is not evidence of blame, poor hygiene or criminality; confidentiality and respectful counselling improve disclosure and contact protection.
Diagnosis
History
Ask duration and pattern of cough, sputum, haemoptysis, fever, night sweats, weight change, appetite, breathlessness and pleuritic pain. Clarify exposure, previous TB, medicines and treatment completion, HIV status, diabetes, pregnancy, renal or liver disease, immunosuppression, smoking and occupational silica exposure. Ask about hoarseness, swallowing difficulty, lymphadenopathy and symptoms of extrapulmonary or disseminated disease. Record specimen dates and every prior antibiotic or TB drug rather than accepting “treatment taken” as a complete history.
Examination
Record temperature, respiratory rate, oxygen saturation, pulse, weight and functional status. Look for respiratory distress, focal crackles, bronchial breathing, clubbing, lymph nodes, pallor, jaundice, oedema, neuropathy, visual symptoms and signs of HIV or disseminated disease. Severe haemoptysis, hypoxia, sepsis, confusion, meningism or pregnancy with significant illness changes urgency. Examination cannot establish infectiousness alone; cough frequency, smear or molecular result, cavitation, treatment response and local infection-control advice must be integrated.
Investigations
Obtain an appropriate respiratory specimen, usually sputum, for an approved rapid molecular test with rifampicin-resistance detection where available. Collect a quality deep specimen with instruction and infection-control precautions; induced sputum or bronchoscopy is specialist-directed when sputum cannot be obtained. Chest radiography supports assessment; CT is not a routine substitute for microbiology but can clarify complications or competing disease. Smear microscopy, culture, line-probe assay and phenotypic susceptibility testing are used according to the resistance pathway. Test for HIV with consent, diabetes, pregnancy when relevant, blood count, renal and liver function, and baseline visual or neuropathy assessment when regimen drugs require it.
Differential Diagnosis
Chronic cough and weight loss have a broad differential. Bacterial pneumonia, lung cancer, fungal disease, nocardiosis, bronchiectasis, COPD, asthma, sarcoidosis, pneumoconiosis, pulmonary embolism, heart failure and gastro-oesophageal reflux can mimic or coexist with TB. In India, melioidosis, endemic fungi and non-tuberculous mycobacteria may require specialist consideration. A cavity is not synonymous with TB, and a negative smear should not end evaluation when suspicion remains.
Nontuberculous mycobacteria can produce chronic nodular or cavitary disease but differ in treatment and may contaminate specimens; species identification and repeated compatible samples matter. HIV may produce atypical radiology and opportunistic infection. Pulmonary oedema, malignancy and inflammatory disease can cause constitutional symptoms. Haemoptysis also requires assessment for bronchiectasis, cancer, pulmonary embolism, aspergillosis and vascular causes.
A positive tuberculin skin test or IGRA indicates immune sensitisation, not active pulmonary disease; it should not be used alone to diagnose contagious TB. Conversely, a negative immune assay does not exclude active disease. If molecular testing is negative but suspicion remains high, obtain repeat or alternative specimens, review imaging and seek respiratory or TB expertise. Never add corticosteroids solely because a chest image looks inflammatory until infection and the indication are reviewed.
Management
Start treatment through NTEP or an authorised TB service after collecting diagnostic specimens whenever the patient is stable; do not create avoidable delays in severe disease. Drug-susceptible pulmonary TB uses the current programme regimen, typically an intensive phase containing rifampicin, isoniazid, pyrazinamide and ethambutol followed by a continuation phase, with exact duration, formulation and exceptions governed by the latest NTEP guideline. Rifampicin resistance changes the pathway; never continue a failing first-line combination while awaiting an informal opinion.
Drug-resistant TB requires rapid referral, resistance testing and an all-oral regimen selected by the programme according to the resistance pattern, previous exposure, pregnancy, QT risk, drug interactions and organ function. Do not add a single drug to a failing regimen. Adherence support may include counselling, digital or community follow-up, nutrition linkage and management of adverse effects; directly observed treatment is not the only measure of supportive care.
Reduce transmission with respiratory hygiene, ventilation, mask use and an individualised infectiousness plan. Hospitalise when hypoxia, major haemoptysis, respiratory failure, sepsis or unsafe home conditions require it. Treat HIV, diabetes, malnutrition and smoking alongside TB. Patients should receive a written regimen, contact number, review schedule, symptom warnings and advice not to share medicines. Treatment completion requires bacteriological and clinical follow-up, not merely disappearance of cough.
Prescribing Information
Programme prescribing is regimen-specific and must use current NTEP weight bands, formulations and resistance categories; this guide intentionally does not provide a substitute dose table. Confirm the molecular resistance result, previous exposure, allergies, pregnancy, HIV medicines, renal and liver function and QT-prolonging drugs. Rifampicin has extensive interactions, including reduced exposure to many antiretrovirals, hormonal contraceptives, anticoagulants, anticonvulsants and transplant medicines; an HIV or specialist pharmacist should coordinate changes.
Explain expected orange discoloration of body fluids with rifampicin without dismissing jaundice, severe abdominal symptoms or dark urine. Check for hepatitis, persistent vomiting, confusion or marked fatigue as possible hepatotoxicity. New visual blurring or colour-vision change requires urgent ethambutol review. Numbness or burning feet requires prompt assessment and programme-directed pyridoxine. Hearing or balance symptoms matter when an injectable or other ototoxic medicine is used in a resistant regimen. Palpitations or syncope need ECG and electrolyte assessment when QT-active drugs are present.
Monitor symptoms, weight, adherence, sputum or molecular response, blood counts, liver and renal tests, glucose, ECG, vision and neurological status according to the selected regimen. Pregnancy, breastfeeding, HIV, renal disease and liver disease need expert review rather than stopping effective treatment independently. Avoid unregulated fixed-dose combinations or leftover tablets. Record adverse reactions and notify pharmacovigilance systems; a patient must know whom to call before the next dose.
When to Refer
Urgent hospital referral is required for hypoxia, respiratory failure, massive or recurrent haemoptysis, shock, altered consciousness, severe drug reaction, jaundice with systemic illness, inability to take medicines, suspected meningitis, spinal cord compression, pregnancy with severe disease or possible disseminated TB. Stabilise airway and circulation and use appropriate respiratory precautions during transfer. A patient coughing blood should not be sent alone on public transport.
Refer promptly to the district drug-resistant TB centre or specialist team for rifampicin resistance, treatment failure, recurrence after a full course, persistent positive cultures, serious adverse effects, complex HIV co-treatment, renal or hepatic failure, pregnancy, childhood disease, suspected non-tuberculous mycobacteria or diagnostic uncertainty. Contact tracing and public-health teams should be involved for household, workplace, school, hostel and congregate exposures.
Referral documentation should include molecular and smear results, specimens and dates, imaging, all previous medicines and doses if known, treatment interruptions, weight, HIV and diabetes status, adverse effects, pregnancy, contacts and the specific decision needed. In India, use NTEP notification and specimen-transport channels; do not duplicate or fragment records when a patient changes provider. Stable patients still need a named clinician and date for review, not an open-ended instruction to return if worse.
Red Flags
Emergency red flags are severe breathlessness, falling oxygen saturation, cyanosis, confusion, syncope, shock, large-volume haemoptysis or rapidly worsening chest pain. Suspect massive airway bleeding, respiratory failure, pneumothorax, sepsis or disseminated disease. New severe headache, neck stiffness, focal deficit, vomiting or altered behaviour may indicate TB meningitis and requires immediate specialist care. A child with lethargy, poor feeding, respiratory distress or contact exposure needs urgent paediatric assessment.
During treatment, jaundice, persistent vomiting, severe abdominal pain, confusion, bleeding, rash with mucosal involvement, facial swelling, fever with cytopenia, visual change, new neuropathy, hearing loss, palpitations or fainting may represent serious toxicity. Do not advise a patient to simply “push through” these symptoms. Contact the TB team immediately; decisions to hold, replace or reintroduce drugs require a supervised resistance-preserving plan.
Public-health red flags include ongoing cough with poor ventilation, a child or immunocompromised household contact, missed doses, treatment interruption, unreported private-sector care, suspected drug resistance or inability to isolate safely. The service should respond with practical support, not stigma. Persistent symptoms or positive tests after treatment starts require adherence, absorption, resistance, alternative diagnosis and specimen-quality review; repeated empirical additions risk creating further resistance.
Indian Clinical Context
NTEP is India's programme framework for notification, molecular diagnosis, drug-susceptibility testing, differentiated care, adherence support, contact investigation and free or supported treatment. Exact algorithms, weight bands, duration and eligible regimens change as national guidance is updated; clinicians must use the current NTEP manuals and district instructions. Private providers should notify and coordinate rather than run an undocumented parallel course. Nikshay or its current successor is a programme system, not a replacement for clinical judgement.
India's diversity affects implementation: urban slums, remote villages, prisons, mines, hostels, tribal communities and migrant work may have different transport, ventilation, nutrition and privacy barriers. Explain disease and infectiousness in the patient's language, protect confidentiality and involve family only with consent except where public-health law requires action. Link eligible people to nutrition, social-protection, HIV, diabetes, tobacco-cessation and mental-health services.
A positive result does not justify blaming a household; contact evaluation is an act of protection. Children and immunocompromised contacts need priority, with preventive treatment considered only after active disease is excluded and current policy is checked. Preserve records when patients cross public and private systems. This guide does not claim a current national incidence estimate, provide legal advice or replace NTEP, NACO, CDSCO labels, state policy or an expert TB team.
NMC Competency Mapping
Pulmonary TB links NMC CBME learning in respiratory history and examination, microbiology, pharmacology, community medicine, infectious disease, HIV care, communication and professionalism. Learners should recognise prolonged cough and constitutional symptoms, obtain a respectful exposure and treatment history, assess severity, collect a good sputum specimen safely and explain the distinction between infection, active disease, infectiousness and drug resistance.
They should interpret chest radiography cautiously, describe rapid molecular testing and rifampicin-resistance detection, and state why smear-negative disease, atypical HIV disease and non-tuberculous mycobacteria need further assessment. Pharmacology competencies include rifampicin interactions, ethambutol visual toxicity, isoniazid neuropathy and hepatotoxicity monitoring, but independent programme prescribing requires supervised training and current NTEP documents.
Community competencies include notification, confidentiality, contact investigation, ventilation, stigma reduction, adherence support and linkage to HIV, diabetes and nutrition services. An OSCE may test counselling a newly diagnosed patient, managing haemoptysis, reviewing a treatment interruption or explaining why a household child needs evaluation. Faculty should verify exact competency codes against the current NMC compendium and separate undergraduate learning outcomes from specialist TB authority.
Key Exam Pearls for NEET PG
Pulmonary TB is diagnosed by integrating compatible illness with microbiology and imaging; a positive IGRA or tuberculin test alone indicates immune response, not active contagious disease. Rapid molecular testing is preferred because it can identify M tuberculosis and rifampicin resistance early. A negative smear does not exclude disease. Always ask about previous TB treatment, adherence and resistance before selecting a regimen.
Drug-susceptible programme therapy uses an intensive rifampicin-isoniazid-pyrazinamide-ethambutol phase followed by continuation therapy, but current NTEP guidance determines exact duration, formulation and exceptions. Rifampicin causes major drug interactions. Ethambutol toxicity is optic neuropathy; isoniazid can cause peripheral neuropathy and hepatotoxicity; pyrazinamide can cause hepatotoxicity and hyperuricaemia. Orange urine from rifampicin is expected; jaundice is not.
Rifampicin-resistant disease requires rapid programme referral and a resistance-guided all-oral regimen; never add one drug to a failing regimen. Notify confirmed disease, assess household contacts and prioritise children and immunocompromised contacts. Ventilation, masks and cough etiquette reduce exposure. HIV testing with consent, diabetes screening, pregnancy review, nutrition and adverse-effect counselling are part of TB care, not optional extras. Patient-centred care also includes stigma-sensitive language, assessment of food and transport barriers, a plan for missed doses, and documentation that the patient understood when to seek urgent help.
Frequently Asked Questions
Can a normal chest radiograph rule out pulmonary tuberculosis in a person with chronic cough?
No. Early, paucibacillary, HIV-associated, paediatric and immunosuppressed disease may have subtle or normal radiography. Persistent compatible symptoms require a quality respiratory specimen for approved molecular testing and clinical review. Conversely, an abnormal film is not proof of TB; malignancy, fungal disease, bronchiectasis and other conditions can look similar.
What should a clinician do when a rapid molecular test detects rifampicin resistance?
Treat it as a programme-changing result and contact the district drug-resistant TB or specialist service promptly. Preserve the specimen and arrange the recommended additional resistance testing. Do not continue an apparently failing first-line combination, add one drug, or select a resistant regimen from an internet table. Review previous treatment, HIV medicines, pregnancy, renal and liver function and the patient's ability to attend monitoring.
When is a person with pulmonary tuberculosis considered safe to stop infection-control precautions?
There is no single symptom or calendar rule that applies to every patient. Infectiousness depends on the diagnosis, sputum or molecular findings, cough, cavity burden, treatment response, adherence, ventilation and local public-health advice. Continue masks, cough etiquette and ventilation while the TB team assesses risk. A patient should receive a written, individualised plan before returning to crowded work, school or shared sleeping spaces.
How should household contacts be managed after pulmonary TB is diagnosed?
Notify and involve the current NTEP or public-health team, then identify household and other close contacts respectfully and confidentially. Prioritise children under five and immunocompromised people for prompt evaluation. Active disease must be excluded before preventive treatment is considered, and the current programme protocol determines testing, follow-up and regimen. Contact tracing is supportive protection, not an accusation of poor hygiene or blame.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic